Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
Zheng Wang, Jia Fan, Shao‐Lai Zhou, Yun‐Fan Sun, Fei Liang, Yuan Ji, Fangming Gu, Tao Li, Li Peng, Tao Peng, Xiaolun Huang, Zhen‐Bin Ding, Dousheng Bai, Bangde Xiang, Guang Tan, Tianfu Wen, Yongyi Zeng, Feng Han, Yu Zhang, Shengdong Wu, Haitao Zhao, Yi Chen, Guo‐Ming Shi, Zhiguo Hou, Ying Sun, Wenqing Zhu, Jian Zhou
Topics & Concepts
MedicinePerioperativeHepatocellular carcinomaSurgeryOverall survivalRandomized controlled trialClinical trialResectionCarcinomaInternal medicineIntention-to-treat analysisPhases of clinical researchOncologyCenter (category theory)Proportional hazards modelHepatectomySurgical resectionSurvival rateMEDLINEHepatocellular Carcinoma Treatment and PrognosisCancer, Stress, Anesthesia, and Immune ResponseCancer Immunotherapy and Biomarkers